These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30255136)

  • 21. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitors in liver transplant: a case series.
    Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
    J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
    Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
    Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
    Nguyen LS; Ortuno S; Lebrun-Vignes B; Johnson DB; Moslehi JJ; Hertig A; Salem JE
    Eur J Cancer; 2021 May; 148():36-47. PubMed ID: 33721705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy before liver transplant in unresectable hepatocellular carcinoma: a case report.
    Ohm H; Khwaja R; Karachiwala H
    J Gastrointest Oncol; 2023 Dec; 14(6):2644-2649. PubMed ID: 38196545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database.
    Austin MT; Leys CM; Feurer ID; Lovvorn HN; O'Neill JA; Pinson CW; Pietsch JB
    J Pediatr Surg; 2006 Jan; 41(1):182-6. PubMed ID: 16410130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A clinicopathologic study on complications of orthotopic liver transplantation in 54 patients with chronic hepatitis B virus infection].
    Pei F; Zheng J; Du J; Zhong HH; Yang JP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):408-14. PubMed ID: 18677390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.
    Ramadori G; Bosio P; Moriconi F; Malik IA
    BMC Cancer; 2018 Mar; 18(1):257. PubMed ID: 29510685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.
    Goldman JW; Abdalla B; Mendenhall MA; Sisk A; Hunt J; Danovitch GM; Lum EL
    BMC Nephrol; 2018 Aug; 19(1):210. PubMed ID: 30126374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventions for preventing thrombosis in solid organ transplant recipients.
    Surianarayanan V; Hoather TJ; Tingle SJ; Thompson ER; Hanley J; Wilson CH
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD011557. PubMed ID: 33720396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic study on complications of orthotopic liver transplantation in 54 patients with chronic hepatitis B viral infection.
    Pei F; Shang K; Jiang B; Wang H; Mei F; Zhang Y; Du J; Zhong H; You J
    Hepatol Int; 2013 Jun; 7(2):468-76. PubMed ID: 26201779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
    Venkatachalam K; Malone AF; Heady B; Santos RD; Alhamad T
    Transplantation; 2020 May; 104(5):1041-1047. PubMed ID: 31415036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma.
    Ishikawa G; Sugiyama T; Ito T; Otsuka A; Miyake H
    Int Cancer Conf J; 2021 Apr; 10(2):116-118. PubMed ID: 33786286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant.
    Satapathy SK; Das K; Kocak M; Helmick RA; Eason JD; Nair SP; Vanatta JM
    Clin Transplant; 2018 May; 32(5):e13246. PubMed ID: 29577449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
    Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
    Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single-center experience of retransplantation for liver transplant recipients with a failing graft.
    Chen GH; Fu BS; Cai CJ; Lu MQ; Yang Y; Yi SH; Xu C; Li H; Wang GS; Zhang T
    Transplant Proc; 2008 Jun; 40(5):1485-7. PubMed ID: 18589134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Concomitant use of nivolumab and immunosuppressants in a renal transplant patient].
    Pluchart H; Ferrer L; Giovannini D; Tetaz R; Pinsolle J; Stephanov O; Giaj Levra M; Moro-Sibilot D; Toffart AC
    Rev Mal Respir; 2019 Nov; 36(9):1064-1068. PubMed ID: 31611026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
    Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
    Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.